Skip to main content

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Featured Section: Combination Strategies

The Combination Strategies section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases. Edited by Paolo A Ascierto, the section considers research and review articles from the field. 


Read the latest articles in the Combination Strategies section

Featured Research: Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating disease accompanied by muscular fatigue and pain. A functional measure to assess muscle fatigability of ME/CFS patients is, however, not established in clinical routine. 


In this study, Jäkel and colleagues aimed to evalulate muscle fatigability as a diagnostic tool and its correlation with clinical parameters by assessing repeat maximum handgrip strength (HGS). Findings revealed that patients with ME/CFS have reduced Fmax and Fmean HGS compared to healthy controls. Repeat HGS assessment is a sensitive diagnostic test to assess muscular fatigue and fatigability and an objective measure to assess disease severity in ME/CFS.

Featured Review: Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Chronic Fatigue Syndrome or Myalgic Encephaloymelitis (ME/CFS) is a frequent debilitating disease with an enigmatic etiology. The researchers' hypothesis published previously considers ME/CFS as a disease caused by a dysfunctional autonomic nervous system: sympathetic overactivity in the presence of vascular dysregulation by ß2AdR dysfunction causes predominance of vasoconstrictor influences in brain and skeletal muscles, which in the latter is opposed by the metabolically stimulated release of endogenous vasodilators (functional sympatholysis).


In this article, Wirth & Scheibenbogen explain the mechanisms underlying the energetic disturbance in muscles and merge with the first hypothesis. According to the hypothesis dysfunctions of the ß2AdR or post-receptor mechanisms, of the NHE1, the Na+/K+ATPase, the NCX, the RAAS and the KKS could be causally involved in ME/CFS and should therefore be further investigated. 

Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 

Articles

  1. Authors: Thomas E Ichim, Fabio Solano, Eduardo Glenn, Frank Morales, Leonard Smith, George Zabrecky and Neil H Riordan

    Content type: Review

Thank you to the JTRM reviewers!

Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020). 

Our companion journal

Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine. 

The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.

Explore Translational Medicine Communications

Introducing two new sections to Journal of Translational Medicine

Translational Metagenomics

© Kateryna_Kon / stock.adobe.com


Led by Section Editor Souhaila Al Khodor, this new section aims to fill the gap between basic research, translational medicine, and high-throughput data analysis for the human microbiome by providing innovative and novel scientific ideas.


Translational Metagenomics encompasses studies about the development and application of metagenomics, metatranscriptomics, microbial metabolomics or novel bioinformatics tools used to improve our knowledge on the microbiome. The section is especially interested in studies that go beyond description of the microbial composition and include experimental models used to support the proposed role of the microbiome in human health and diseases.

Emerging Therapeutics

© Parilov / stock.adobe.com


Led by Section Editor Gennaro Ciliberto, this exciting section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments.


Emerging Therapeutics is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.

Editor-in-Chief: Francesco Marincola, Kite Pharma, USA

Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.

Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:

Annual Journal Metrics